PARP抑制剂在卵巢癌中的最新临床证据与进一步开发
综述回顾了奥拉帕利、尼拉帕利和芦卡帕利作为铂敏感复发性卵巢癌维持治疗的关键试验,三项III期试验显示无进展生存期显著改善,但总生存数据待定且长期安全性经验有限。PARP抑制剂已改变卵巢癌管理,正在探索治疗而非维持及联合抗血管生成和免疫治疗等策略。
要点
- 奥拉帕利、尼拉帕利和芦卡帕利已获批用于铂敏感复发性卵巢癌维持治疗。
- NOVA、SOLO2和ARIEL3三项III期试验显示PARP抑制剂维持治疗显著改善无进展生存期。
- 总生存数据待定,长期安全性经验有限,遗传特征、给药方案、耐受性和可及性影响患者选择。
核心结论
- PARP抑制剂已改变卵巢癌管理并改变许多患者的疾病进程。
- PARP抑制剂在铂敏感复发性卵巢癌维持治疗中显著改善无进展生存期。
研究设计与样本
- 综述回顾了导致奥拉帕利、尼拉帕利和芦卡帕利获批用于铂敏感复发性卵巢癌维持治疗的关键试验。
- 讨论了三项III期试验(NOVA、SOLO2和ARIEL3)的设计和患者人群差异。
主要发现
- 三项III期试验显示PARP抑制剂维持治疗在铂类治疗后完全或部分缓解的铂敏感卵巢癌患者中显著改善无进展生存期。
- 试验设计和患者人群差异影响从这些试验中得出的结论。
- 总生存数据待定,长期安全性经验有限。
临床怎么用
- PARP抑制剂用于铂敏感复发性卵巢癌维持治疗,近期获批不考虑BRCA突变或同源重组缺陷状态。
- 遗传特征、给药方案、耐受性和可及性可能影响患者选择和PARP抑制剂使用场景。
局限性
- 总生存数据待定。
- 长期安全性经验有限。
- 试验设计和患者人群差异影响结论推导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
For several decades, the systemic treatment of ovarian cancer has involved chemotherapy, with the relatively recent addition of antiangiogenic strategies given with chemotherapy and in the maintenance setting. In the past decade, numerous poly(ADP-ribose) polymerase (PARP)-inhibiting agents have been assessed. We review key trials that have led to the approval of three PARP inhibitors-olaparib, niraparib and rucaparib-as maintenance therapy for platinum-sensitive recurrent ovarian cancer. We discuss the efficacy and safety of these agents in the populations studied in clinical trials. We then provide an overview of the numerous avenues of ongoing research for PARP inhibitors in different treatment settings: as treatment rather than maintenance strategies and in combination with other anticancer approaches, including antiangiogenic and immunotherapeutic agents. Three phase III trials (NOVA, SOLO2 and ARIEL3) demonstrated remarkable improvement in progression-free survival (PFS) with PARP inhibitors given as maintenance therapy in patients with complete or partial response after platinum-based therapy for platinum-sensitive ovarian cancer. Differences in trial design and patient populations influence the conclusions that can be drawn from these trials. Overall survival data are pending and there is a limited experience regarding long-term safety. PARP inhibitors have transformed the management of ovarian cancer and have changed the course of disease for many patients. Although recent approvals are irrespective of BRCA mutation or homologous repair deficiency status, genetic profiles, as well as dosing schedules, tolerability and affordability, may influence patient selection and the setting in which PARP inhibitors are used. The development and evolution of PARP inhibitors continue, with new agents, strategies, combinations and indications under intensive evaluation.
引用
- Mirza MR, Pignata S, Ledermann JA, et al. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer. Ann Oncol. 2018. PMID: 29750420. doi:10.1093/annonc/mdy174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。